[Influence of Comorbidities on Revision Rate within the First Year after Primary Total Hip Arthroplasty]
Roman Nesslage1, Kerstin Radtke1, Lisa Hohloch2
1Orthopädische Klinik im Diakovere Annastift, Medizinische Hochschule Hannover.
Insights
Comorbidities increase the risk of revision surgery after total hip arthroplasty (THA). Conditions like anemia, obesity, and substance abuse significantly raise re-operation rates within the first year, impacting hip replacement survival.
Area of Science:
- Orthopedic Surgery
- Health Services Research
- Epidemiology
Background:
- Total hip arthroplasty (THA) is a common procedure with significant clinical and economic implications for revision surgeries.
- Understanding factors influencing THA survival is crucial for optimizing patient outcomes and healthcare resource allocation.
- Comorbid diseases represent a potential area for investigation regarding their impact on early THA revision rates.
Purpose of the Study:
- To identify comorbid diseases in patients undergoing primary total hip arthroplasty (THA).
- To evaluate the influence of these comorbid diseases on the risk of early revision surgery after THA.
- To provide data for improved pre- and post-operative risk assessment and patient selection for THA.
Main Methods:
- Retrospective study including 867 patients undergoing primary THA.
- Analysis of all revision surgeries within one year of primary implantation.
- Comorbidities identified using administrative data based on the Elixhauser definition (30 diseases).
- Statistical analysis using Cox regression and Fisher's exact test to assess correlations.
Main Results:
- 41 patients (4.7%) required re-operation within the first year post-THA.
- The presence of one or more comorbidities was significantly associated with an increased risk of revision (p < 0.05).
- Specific comorbidities linked to higher revision risk include deficiency anemia, obesity, drug abuse, alcohol abuse, fluid/electrolyte disorders, and peripheral vascular disorders.
Conclusions:
- The total number and specific types of comorbidities are independently associated with an increased risk of early re-operation after THA.
- Identifying and managing comorbidities can aid in risk stratification for patients undergoing THA.
- This evidence supports tailored pre- and post-operative management strategies to improve THA outcomes.
Abstract:
Background Total hip arthroplasty (THA) is very frequently performed. Despite low complication rates, revisions play an important clinical and economical role. The aim of this study was to identify comorbid diseases of patients undergoing primary THA and their potential influence on the survival of hip replacements. Patients/Material and Methods A total of 867 patients were included in this retrospective study. All revisions were reviewed that took place at our hospital within one year of primary implantation of THA. Comorbid diseases were detected by administrative data, using the Elixhauser definition, which includes thirty diseases. The Cox regression model and Fisher's exact test were used to examine correlations between comorbidities and risk of revision. Results 41 Patients required re-operation within the first year of surgery. The presence of one or more of the analysed comorbidities was associated with a greater risk of revision. Deficiency anemia, obesity, drug abuse, alcohol abuse, fluid and electrolyte disorders and peripheral vascular disorders were associated with increased risk of revision (p < 0.05 for all comparisons).
Conclusion:
The total number of comorbidities and specific comorbid diseases was independently associated with an increased risk of re-operation within the first year of total hip arthroplasty. This information could be helpful in pre- and post-operative risk adjustment and patient selection.
Related Concept Videos
01:26Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
01:22Mitral Valve Prolapse II: Assessment and Management